Table 2.
Clinical characteristics of the study subjects.
| Variables | Subtypes | n (%) |
|---|---|---|
| Comorbidity: | ||
| None | 130 (74.7) | |
| Substance | 27 (15.5) | |
| Cannabis | 12 (44.4) | |
| Opiates | 5 (18.5) | |
| Methamphetamine | 17 (63.0) | |
| Inhalants | 1 (3.7) | |
| Alcohol | 4 (14.8) | |
| Others | 2 (7.4) | |
| Depression | 9 (5.2) | |
| Medical Illness | ||
| Diabetes Mellitus | ||
| Yes | 22 (12.6) | |
| No | 137 (78.7) | |
| Unknown | 15 (8.6) | |
| Hypertension | ||
| Yes | 23 (13.2) | |
| No | 136 (78.2) | |
| Unknown | 15 (8.6) | |
| Ishaemic heat disease | ||
| Yes | 4 (2.3) | |
| No | 155 (89.1) | |
| Unknown | 15 (8.6) | |
| Dyslipidaemia | ||
| Yes | 19 (10.9) | |
| No | 140 (80.5) | |
| Unknown | 15 (8.6) | |
| Smoking | Yes | 97 (55.7%) |
| No | 77 (44.3%) | |
| Treatment | ||
| Antipsychotic Oral | n (%) | |
| Typical | Total | 62 (35.6) |
| Chlorpromazine | 11 (17.4) | |
| Haloperidol | 14 (22.6) | |
| Trifluoperazine | 2 (3.2) | |
| Perphenazine | 1 (1.6) | |
| Sulpiride | 28 (45.2) | |
| Others | 6 (9.8) | |
| Atypical | Total | 102 (58.6) |
| Risperidone | 57 (55.9) | |
| Olanzepine | 21 (20.6) | |
| Quetiapine | 8 (7.8) | |
| Clozapine | 11 (10.8) | |
| Aripiprazole | 3 (2.9) | |
| Others | 2 (2.0) | |
| Depot | Total | 67 (38.5) |
| Modecate | 11 (16.4) | |
| Fluanxol | 49 (73.1) | |
| Zuclopenthixol | 2 (3.0) | |
| Paliperidone | 4 (6.0) | |
| Others | 1 (1.5) | |
| Combination therapy | Yes | 62 (35.6) |
| Type of Combination | Risperidone and I.M. Fluanxol | 24 (39.3) |
| Risperidone and I.M. Modecate | 3 (4.9) | |
| Chlorpromazine and I.M. Fluanxol | 5 (8.2) | |
| Sulpiride and I.M. Fluanxol | 4 (6.6) | |
| Other combinations | 25 (41.0) | |
I.M. = Intramuscular injection.